Ms.Zhang Jinhua established IASO Biotechnology in March 2017 and is currently Chairman and Chief Executive Officer of the company.
Ms.Zhang holds a Master’s degree in law. She has worked in investment bank as well as securities law firm, and gained rich experience in both financing and securities law. In her twenty-year professional career in capital markets, M&A, and corporate restructuring, Ms. Zhang has helped dozens of companies to be successfully listed in the domestic as well as overseas markets. In 2015, Ms. Zhang also invested in a cell therapy company as an angel investor.
Dr. Wang joined IASO Biotherapeutics in March 2020, and is currently the company’s Executive President.
Dr. Wang graduated from Anhui Medical University with a Bachelor of Medicine (B.M.) degree. He was an orthopedic resident doctor and attending physician in Shanghai TCM Integrated Hospital. Dr. Wang subsequently obtained Master of Medicine (M.M.) degree from Tongji University and Doctor of Medicine (M.D.) degree from Tongji University/ Universität Würzburg, as well as doctorate in molecular biology (Ph.D.) from University of Aberdeen. He was a post-doctoral fellow in the University of Connecticut Health Center, during which he published over 20 papers in SCI-indexed journals on cell therapies in leading publications including Clinical Cancer Research and Blood.
Dr. Wang joined the pharma industry in 2013, having worked with Cellular Biomedicine Group (NASDAQ: CBMG), JW Therapeutics (HKEX: 02126), and Simecere Pharmaceutical Group (SEHK: 02096) as Medical Director, Head of Clinical Development and Head of Clinical Sciences, respectively.
Dr. Wang has been exploring cell therapies since 2006. As a key member of the project team, he contributed to the successful investigational new drug application for the first CD19-targeted CAR-T therapy in China.
He was appointed Chief Medical Officer of IASO Biotherapeutics in March 2020, leading the clinical development team in the clinical trial of CT103A.
Dr. Fu combines rich experiences in finance with a deep knowledge in science. While at Haitong International and Citigroup he led numerous successful listings of Chinese companies in Hong Kong and the United States, including multiple companies in the healthcare industry. Prior to that, Dr. Fu worked for two law firms－Davis Polk & Wardwell in Hong Kong and Skadden, Arps, Slate, Meagher & Flom in Palo Alto－where he focused on capital markets transactions, including IPOs and bond issuances. Early in his career, he was a scientist at Rigel Pharmaceuticals, a US-based biotechnology company, focusing on research and drug development in the immunology and oncology areas.
Dr. Fu holds a J.D. degree from University of California, Berkeley School of Law, a Ph.D. degree in Molecular Genetics from Washington University School of Medicine in St. Louis, an M.S. degree in Molecular Immunology from Shanghai Institute of Cell Biology, Chinese Academy of Sciences and a B.S. degree in Genetics and Genetic Engineering from Fudan University.
Mr. Zhang joined IASO Biotherapeutics in September 2022, and is currently the company’s Chief Commercial Officer.
Mr. Zhang graduated from Shanghai Medical University with a bachelor's degree in pharmacology, and later obtained an MBA degree from Fudan University. He has been engaged in marketing management in the field of cancer for more than 20 years since 1998, and has profound understanding of pharmaceutical marketing and rich experience in marketing innovative cancer drugs.
He has successively served as the National Sales Director of the Tumor Business Department of Pfizer Inc., the Business Director of the Northern China Tumor Business Department of Merck Serono, the Business Director of the Special Treatment of Bayer Healthcare, and the Deputy Chief Commercial Officer of Fosun Kate Biotechnology.
Mr. Zou joined IASO Biotherapeutics in 2017 and is currently the company’s Director and Vice President for CMC. He has nearly 20 years of experience in GMP management.
Mr. Zou graduated from the National University of Singapore with a Master’s degree in Chemistry, and was previously Quality Director and Quality Authorizer of Sinovac Biotech Ltd. (NASDAQ: SVA). He was also a GMP Expert of Beijing Municipal Medical Products Administration.
Dr. Hu joined IASO Biotherapeutics in January 2018, and is currently the company’s Vice President for Research & Development.
Dr. Hu has a Ph.D. in Molecular Biology from the Institute of Biophysics, Chinese Academy of Sciences. He underwent postdoctoral training in clinical oncology research at the Harvard Medical School and was a Visiting Scholar at Stanford University School of Medicine. Before joining IASO Biotherapeutics, Dr. Hu served as General Manager of Beijing Sirnoa Biotechnology Co., Ltd., and Director of Shaoxing Research Institute of College of Engineering, Peking University. Since returning to China in 2015 Dr. Hu has been involved in research and development of CAR-T cell therapies.
Mr. Cong joined IASO Biotherapeutics in 2022 and is currently the company’s Senior Vice President of General Management. Mr.Cong graduated in Mechanical Engineering from Jiangnan University.
He has successively served as the China Supply Chain Leader of MSD China;Lean Manufacture System Champion of Dupont AP; Director of Supply Chain Management of Novartis Chemical Operation;Head of Supply Chain Management of Boehringer Ingelheim Great China and Vice President of Supply Chain Management of Fosun Kite Biotechnology.
He has 15 years’experience in pharmaceutical supply chain management and 11 years’experience of operation management with profound theoretical and practical experience in chemical medicine and cell therapy supply chain management, world-class supply chain system construction and lean management of production-oriented enterprise.
Dr. Ren Chunli has served as Vice President of Regulatory Affairs at IASO since March 2021. Dr. Ren received her Ph.D. in Molecular Biology from the University of Southern California. Previously she held senior Regulatory Affairs positions at CStone, GSK, Roche and other leading companies with over 12 years of broad regulatory management expertise and IND/ NDA filings experiences spanning across biological and oncology products. She has led CStone’s team to complete more than 10 IND/NDA filings.